Oncotarget

Clinical Research Papers:

Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma

Sheng-Kai Liang, Min-Shu Hsieh, Meng-Rui Lee, Li-Ta Keng, Jen-Chung Ko and Jin-Yuan Shih _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:90430-90443. https://doi.org/10.18632/oncotarget.19563

Metrics: PDF 1009 views  |   HTML 2409 views  |   ?  


Abstract

Sheng-Kai Liang1, Min-Shu Hsieh2, Meng-Rui Lee1, Li-Ta Keng1, Jen-Chung Ko1 and Jin-Yuan Shih3

1Department of Internal Medicine, National Taiwan University Hospital Hsinchu Branch, Hsinchu, Taiwan

2Department of Pathology, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan

3Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan

Correspondence to:

Jin-Yuan Shih, email: jyshih@ntu.edu.tw

Keywords: afatinib, EGFR mutation-positive, first-line therapy, lung adenocarcinoma, real-world study

Received: March 15, 2017     Accepted: July 19, 2017     Published: July 26, 2017

ABSTRACT

We evaluated the real-world efficacy and side effects of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma. The medical records of patients receiving afatinib as a first-line therapy after National Health Insurance reimbursement between May 2014 and January 2016 were reviewed, and information on patient characteristics and treatment courses were collected consecutively. Rebiopsy tissue was collected for EGFR mutation and MET amplification analyses. MET amplification was detected by fluorescence in situ hybridization and immunohistochemistry. In total, 140 patients were enrolled (median follow-up, 18.0 months). No significant differences in side effects, treatment responses, progression-free survival, or brain metastasis control were observed between patients receiving 40 mg versus < 40 mg of afatinib during the first 6 months. Patients with significant pretreatment weight loss (> 10.0% in 6 months) had a shorter median progression-free survival. Patients with brain metastases had a poorer Eastern Cooperative Oncology Group performance status and were associated with a shorter median progression-free survival. Nine patients (32.1%) had a p.T790M mutation and only 1 patient gained MET amplifications after disease progression. Afatinib is effective as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma. Afatinib dosage does not affect clinical efficacy and drug-related side effects.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 19563